Adma Biologics Inc. (ADMA) Stock Price Down 22.3%
Adma Biologics Inc. (NASDAQ:ADMA)’s share price fell 22.3% during trading on Monday . The stock traded as low as $5.00 and last traded at $6.10, with a volume of 775,071 shares trading hands. The stock had previously closed at $7.85.
Several research firms have commented on ADMA. Raymond James Financial Inc. downgraded shares of Adma Biologics from a “strong-buy” rating to a “market perform” rating in a report on Monday. Maxim Group downgraded shares of Adma Biologics from a “buy” rating to a “hold” rating in a report on Monday.
The firm’s market cap is $79.78 million. The company’s 50-day moving average is $6.76 and its 200-day moving average is $6.39.
Adma Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Friday, May 13th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.06. Analysts anticipate that Adma Biologics Inc. will post ($1.39) EPS for the current fiscal year.
ADMA Biologics, Inc is a biopharmaceutical company that develops and manufactures specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. The company’s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.